The role of CD8+ T-cell clones in immune thrombocytopenia
May 1, 2023
Thought provoking article regarding a non-antibody mediated mechanism in chronic ITP.
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma
May 1, 2023
Pembro + AVD for 1L treatment of cHL was associated with excellent responses, PFS and clearance of ctDNA. IO+chemo seems to be a growing trend in HL in various settings and theses response rates in non-Bleo regimens are very encouraging. The ongoing trial NCT05675410 comparing BV+AVD vs. Nivo+AVD should be a pivotal trial when complete.
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer
May 1, 2023
Alternative dosing of exemestane given TIW vs. once weekly treatment in adjuvant breast cancer, end-point was serum estradiol measurements and not survival metrics. Would like to see this done on a larger scale or with other end-points, but for those who are not tolerating standard dosing, this could be an option to consider.
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
May 1, 2023
Pembro + ICE seems to be a compelling option in the 2L setting for transplant eligible cHL patients, however this is not yet in guidelines.
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538
May 1, 2023
Twice-Daily radiation therapy is a long-standing SOC for LS-SCLC based upon improved OS in Intergroup0096, published nearly 25 years ago in 1999. This study compared 45 Gy at 1.5 Gy/fx BID vs. 45 Gy at 1.8 Gy/day. This regimen, however, has been slow to be adopted due to the inconvenience of BID therapy, as well as the modest radiation dose in control arm.
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy
May 1, 2023
Throwback by JCO! Docetaxel vs Pemetrexed in 2L NSCLC showed similar OS/PFS outcomes, but Pemetrexed was tolerated better particularly in terms of myelosuppression. Pemetrexed was active in squamous cancers as well.
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
May 1, 2023
Interesting approach where endocrine therapy was changed after progression on 1L therapy and the ribociclib was continued.
CT Radiomics for Predicting Pathological Complete Response of Axillary Lymph Nodes in Breast Cancer After Neoadjuvant Chemotherapy: A Prospective Study
April 1, 2023
A way to avoid axillary dissection, with more neoadjuvant therapy treatments, this may help avoid unnecessary axillary dissection.Probably needs more validation with larger studies but is a good start.Also, the first related to radiological findings, so welcome input from our FCS Radiologists.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
April 1, 2023
New criteria for response to therapy in high grade MDS, focuses on pt centered outcomes.
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
April 1, 2023
Neoadjuvant immunotherapy is gaining momentum in breast (triple negative) and lung cancer, now showing promise in MSI high tumors.
